CHAMPIONS ONCOLOGY, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$1.16 million for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-07-27
- CHAMPIONS ONCOLOGY, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2026 was -$1.16M, a 126.30% decline from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $4.43M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2026-04-30 | -$1.16M 10-K · filed 2026-07-27 |
| 2025-04-30 | $4.43M 10-K · filed 2026-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |